Anti-Human Coagulation Factor XI Reference Antibody (Osocimab, RUO)

Description: Osocimab (BS10325) is a research-grade recombinant antibody targeting Plasma thromboplastin antecedent. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Plasmathromboplastinantecedent,PTA,CoagulationfactorXI,F11,FXI
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BAY1213790,CAS:2056878-75-0,FXI,FXIa
Background: Coagulation factor XI (F11) is a ~70 kDa protein. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
Note: For research use only. Not suitable for clinical or therapeutic use.